Current Cardiovascular Risk Reports

, Volume 4, Issue 4, pp 264–270

Is There a Place on the Shelf for Aliskiren?

Article

DOI: 10.1007/s12170-010-0108-6

Cite this article as:
Pimenta, E. Curr Cardio Risk Rep (2010) 4: 264. doi:10.1007/s12170-010-0108-6
  • 25 Downloads

Abstract

Increased renin-angiotensin-aldosterone system (RAAS) activity contributes to target-organ damage and increases cardiovascular risk by elevating blood pressure (BP) and through direct effects on the heart, kidneys, brain, and vascular endothelium. Pharmacologic blockade of RAAS effectively reduces BP and limits or reverses various forms of target-organ damage, including cardiac heart failure, coronary artery disease, chronic kidney disease, and left ventricular hypertrophy. Direct renin inhibitors selectively inhibit human renin and have a therapeutic potential similar to angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Aliskiren is the only orally active direct renin inhibitor that has been approved for the treatment of hypertension and has been shown to have favorable effects on target-organ damage. It effectively reduces BP and has favorable effects on heart failure and proteinuria in diabetic patients. Additional outcome trials are needed to establish the role of this new class of antihypertensive medication in preventing cardiovascular outcomes.

Keywords

HypertensionRenin inhibitorsRenin-angiotensin-aldosterone system

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders, University of Queensland School of MedicinePrincess Alexandra HospitalBrisbaneAustralia
  2. 2.Hypertension Unit, Princess Alexandra HospitalWoolloongabbaAustralia